{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["Influenza virus", "Keap1", "Nrf2", "Oxidative stress", "ROS", "SARS-CoV-2"]], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "34732330", "DateCompleted": {"Year": "2022", "Month": "01", "Day": "27"}, "DateRevised": {"Year": "2023", "Month": "05", "Day": "16"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2021", "Month": "10", "Day": "31"}], "ELocationID": ["10.1016/j.lfs.2021.120111", "S0024-3205(21)01098-5"], "Journal": {"ISSN": "1879-0631", "JournalIssue": {"Volume": "291", "PubDate": {"Year": "2022", "Month": "Feb", "Day": "15"}}, "Title": "Life sciences", "ISOAbbreviation": "Life Sci"}, "ArticleTitle": "Nrf2/Keap1/ARE signaling: Towards specific regulation.", "Pagination": {"StartPage": "120111", "MedlinePgn": "120111"}, "Abstract": {"AbstractText": ["The Nrf2 transcription factor governs the expression of hundreds genes involved in cell defense against oxidative stress, the hallmark of numerous diseases such as neurodegenerative, cardiovascular, some viral pathologies, diabetes and others. The main route for Nrf2 activity regulation is via interactions with the Keap1 protein. Under the normoxia the Keap1 binds the Nrf2 and targets it to the proteasomal degradation, while the Keap1 is regenerated. Upon oxidative stress the interactions between Nrf2 and Keap1 are interrupted and the Nrf2 activates the transcription of the protective genes. Currently, the Nrf2 system activation is considered as a powerful cytoprotective strategy for treatment of different pathologies, which pathogenesis relies on oxidative stress including viral diseases of pivotal importance such as COVID-19. The implementation of this strategy is accomplished mainly through the inactivation of the Keap1 \"guardian\" function. Two approaches are now developing: the Keap1 modification via electrophilic agents, which leads to the Nrf2 release, and direct interruption of the Nrf2:Keap1 protein-protein interactions (PPI). Because of theirs chemical structure, the Nrf2 electrophilic inducers could non-specifically interact with others cellular proteins leading to undesired effects. Whereas the non-electrophilic inhibitors of the Nrf2:Keap1 PPI could be more specific, thereby widening the therapeutic window."], "CopyrightInformation": "Copyright \u00a9 2021 Elsevier Inc. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Molecular Genetics of Intracellular Transport, Institute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov St., 119334 Moscow, Russia. Electronic address: ulasov@genebiology.ru."}], "LastName": "Ulasov", "ForeName": "Alexey V", "Initials": "AV"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Molecular Genetics of Intracellular Transport, Institute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov St., 119334 Moscow, Russia; Faculty of Biology, Moscow State University, 1-12 Leninskiye Gory St., 119234 Moscow, Russia."}], "LastName": "Rosenkranz", "ForeName": "Andrey A", "Initials": "AA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Molecular Genetics of Intracellular Transport, Institute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov St., 119334 Moscow, Russia."}], "LastName": "Georgiev", "ForeName": "Georgii P", "Initials": "GP"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Molecular Genetics of Intracellular Transport, Institute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov St., 119334 Moscow, Russia; Faculty of Biology, Moscow State University, 1-12 Leninskiye Gory St., 119234 Moscow, Russia."}], "LastName": "Sobolev", "ForeName": "Alexander S", "Initials": "AS"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Life Sci", "NlmUniqueID": "0375521", "ISSNLinking": "0024-3205"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "KEAP1 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Kelch-Like ECH-Associated Protein 1"}, {"RegistryNumber": "0", "NameOfSubstance": "NF-E2-Related Factor 2"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "EC 3.4.17.23", "NameOfSubstance": "ACE2 protein, human"}, {"RegistryNumber": "EC 3.4.17.23", "NameOfSubstance": "Angiotensin-Converting Enzyme 2"}], "MeshHeadingList": [{"QualifierName": ["metabolism"], "DescriptorName": "Angiotensin-Converting Enzyme 2"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["physiology"], "DescriptorName": "Antioxidant Response Elements"}, {"QualifierName": ["metabolism"], "DescriptorName": "COVID-19"}, {"QualifierName": ["physiology"], "DescriptorName": "Host-Pathogen Interactions"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["metabolism"], "DescriptorName": "Kelch-Like ECH-Associated Protein 1"}, {"QualifierName": ["methods"], "DescriptorName": "Molecular Targeted Therapy"}, {"QualifierName": ["metabolism"], "DescriptorName": "NF-E2-Related Factor 2"}, {"QualifierName": [], "DescriptorName": "Oxidative Stress"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Ozone"}, {"QualifierName": ["drug effects"], "DescriptorName": "Protein Interaction Maps"}, {"QualifierName": [], "DescriptorName": "Signal Transduction"}, {"QualifierName": [], "DescriptorName": "COVID-19 Drug Treatment"}], "CoiStatement": "The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Halliwell B. Free radicals and other reactive species in disease. eLS. 2015 doi: 10.1002/9780470015902.a0002269.pub3.", "ArticleIdList": ["10.1002/9780470015902.a0002269.pub3"]}, {"Citation": "Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408:239\u2013247. doi: 10.1038/35041687.", "ArticleIdList": ["10.1038/35041687", "11089981"]}, {"Citation": "Finkel T. Oxidant signals and oxidative stress. Curr. Opin. Cell Biol. 2003;15:247\u2013254. doi: 10.1016/s0955-0674(03)00002-4.", "ArticleIdList": ["10.1016/s0955-0674(03)00002-4", "12648682"]}, {"Citation": "D'Autreaux B., Toledano M.B. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat. Rev. Mol. Cell. Biol. 2007;8:813\u2013824. doi: 10.1038/nrm2256.", "ArticleIdList": ["10.1038/nrm2256", "17848967"]}, {"Citation": "Barnham K.J., Masters C.L., Bush A.I. Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 2004;3:205\u2013214. doi: 10.1038/nrd1330.", "ArticleIdList": ["10.1038/nrd1330", "15031734"]}, {"Citation": "Hayes J.D., Dinkova-Kostova A.T. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci. 2014;39:199\u2013218. doi: 10.1016/j.tibs.2014.02.002.", "ArticleIdList": ["10.1016/j.tibs.2014.02.002", "24647116"]}, {"Citation": "Talalay P., Long M.J., Prochaska H.J. Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 1988;85:8261\u20138265. doi: 10.1073/pnas.85.21.8261.", "ArticleIdList": ["10.1073/pnas.85.21.8261", "PMC282409", "3141925"]}, {"Citation": "Moi P., Chan K., Asunis I., Cao A., Kan Y.W. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc. Natl. Acad. Sci. U. S. A. 1994;91:9926\u20139930. doi: 10.1073/pnas.91.21.9926.", "ArticleIdList": ["10.1073/pnas.91.21.9926", "PMC44930", "7937919"]}, {"Citation": "Suzuki T., Yamamoto M. Molecular basis of the Keap1-Nrf2 system. Free Radic. Biol. Med. 2015;88:93\u2013100. doi: 10.1016/j.freeradbiomed.2015.06.006.", "ArticleIdList": ["10.1016/j.freeradbiomed.2015.06.006", "26117331"]}, {"Citation": "Itoh K., Wakabayashi N., Katoh Y., Ishii T., Igarashi K., Engel J.D., Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999;13:76\u201386. doi: 10.1101/gad.13.1.76.", "ArticleIdList": ["10.1101/gad.13.1.76", "PMC316370", "9887101"]}, {"Citation": "Dinkova-Kostova A.T., Holtzclaw W.D., Cole R.N., Itoh K., Wakabayashi N., Katoh Y., Yamamoto M., Talalay P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl. Acad. Sci. U. S. A. 2002;99:11908\u201311913. doi: 10.1073/pnas.172398899.", "ArticleIdList": ["10.1073/pnas.172398899", "PMC129367", "12193649"]}, {"Citation": "Baird L., Yamamoto M. The molecular mechanisms regulating the KEAP1-NRF2 pathway. Mol. Cell. Biol. 2020;40 doi: 10.1128/MCB.00099-20.", "ArticleIdList": ["10.1128/MCB.00099-20", "PMC7296212", "32284348"]}, {"Citation": "Baird L., Yamamoto M. The Keap1-Nrf2 pathway: From mechanism to medical applications. 2020. pp. 125\u2013147.", "ArticleIdList": ["10.1016/B978-0-12-818606-0.00009-2"]}, {"Citation": "Cuadrado A., Rojo A.I., Wells G., Hayes J.D., Cousin S.P., Rumsey W.L., Attucks O.C., Franklin S., Levonen A.L., Kensler T.W., Dinkova-Kostova A.T. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat. Rev. Drug Discov. 2019;18:295\u2013317. doi: 10.1038/s41573-018-0008-x.", "ArticleIdList": ["10.1038/s41573-018-0008-x", "30610225"]}, {"Citation": "Dodson M., Vega M.R., Cholanians A.B., Schmidlin C.J., Chapman E., Zhang D.D. Modulating NRF2 in disease: timing is everything. Annu. Rev. Pharmacol. Toxicol. 2019;59:555\u2013575. doi: 10.1146/annurev-pharmtox-010818-021856.", "ArticleIdList": ["10.1146/annurev-pharmtox-010818-021856", "PMC6538038", "30256716"]}, {"Citation": "Fuse Y., Kobayashi M. Conservation of the Keap1-Nrf2 system: an evolutionary journey through stressful space and time. Molecules. 2017;22 doi: 10.3390/molecules22030436.", "ArticleIdList": ["10.3390/molecules22030436", "PMC6155405", "28282941"]}, {"Citation": "Gacesa R., Dunlap W.C., Barlow D.J., Laskowski R.A., Long P.F. Rising levels of atmospheric oxygen and evolution of Nrf2. Sci. Rep. 2016;6 (27740-doi:10.1038/srep27740)", "ArticleIdList": ["PMC4906274", "27297177"]}, {"Citation": "Tonelli C., Chio I.I.C., Tuveson D.A. Transcriptional regulation by Nrf2. Antioxid. Redox Signal. 2017 doi: 10.1089/ars.2017.7342.", "ArticleIdList": ["10.1089/ars.2017.7342", "PMC6208165", "28899199"]}, {"Citation": "Zenkov N.K., Kozhin P.M., Chechushkov A.V., Martinovich G.G., Kandalintseva N.V., Menshchikova E.B. Mazes of Nrf2 regulation. Biochemistry (Mosc) 2017;82:556\u2013564. doi: 10.1134/S0006297917050030.", "ArticleIdList": ["10.1134/S0006297917050030", "28601065"]}, {"Citation": "Eggler A.L., Liu G., Pezzuto J.M., Breemen R.B., Mesecar A.D. Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. Proc. Natl. Acad. Sci. U. S. A. 2005;102:10070\u201310075. doi: 10.1073/pnas.0502402102.", "ArticleIdList": ["10.1073/pnas.0502402102", "PMC1177374", "16006525"]}, {"Citation": "Fukutomi T., Takagi K., Mizushima T., Ohuchi N., Yamamoto M. Kinetic, thermodynamic, and structural characterizations of the association between Nrf2-DLGex degron and Keap1. Mol. Cell. Biol. 2014;34:832\u2013846. doi: 10.1128/MCB.01191-13.", "ArticleIdList": ["10.1128/MCB.01191-13", "PMC4023822", "24366543"]}, {"Citation": "Lo S.C., Li X., Henzl M.T., Beamer L.J., Hannink M. Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling. EMBO J. 2006;25:3605\u20133617. doi: 10.1038/sj.emboj.7601243.", "ArticleIdList": ["10.1038/sj.emboj.7601243", "PMC1538563", "16888629"]}, {"Citation": "McMahon M., Thomas N., Itoh K., Yamamoto M., Hayes J.D. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a \"tethering\" mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J. Biol. Chem. 2006;281:24756\u201324768. doi: 10.1074/jbc.M601119200.", "ArticleIdList": ["10.1074/jbc.M601119200", "16790436"]}, {"Citation": "Horie Y., Suzuki T., Inoue J., Iso T., Wells G., Moore T.W., Mizushima T., Dinkova-Kostova A.T., Kasai T., Kamei T., Koshiba S., Yamamoto M. Molecular basis for the disruption of Keap1-Nrf2 interaction via Hinge & Latch mechanism. Commun. Biol. 2021;4:576. doi: 10.1038/s42003-021-02100-6.", "ArticleIdList": ["10.1038/s42003-021-02100-6", "PMC8121781", "33990683"]}, {"Citation": "Zhang D.D., Lo S.C., Cross J.V., Templeton D.J., Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol. Cell. Biol. 2004;24:10941\u201310953. doi: 10.1128/MCB.24.24.10941-10953.2004.", "ArticleIdList": ["10.1128/MCB.24.24.10941-10953.2004", "PMC533977", "15572695"]}, {"Citation": "Nioi P., Nguyen T., Sherratt P.J., Pickett C.B. The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation. Mol. Cell. Biol. 2005;25:10895\u201310906. doi: 10.1128/MCB.25.24.10895-10906.2005.", "ArticleIdList": ["10.1128/MCB.25.24.10895-10906.2005", "PMC1316965", "16314513"]}, {"Citation": "Katoh Y., Itoh K., Yoshida E., Miyagishi M., Fukamizu A., Yamamoto M. Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Genes Cells. 2001;6:857\u2013868. doi: 10.1046/j.1365-2443.2001.00469.x.", "ArticleIdList": ["10.1046/j.1365-2443.2001.00469.x", "11683914"]}, {"Citation": "Sun Z., Chin Y.E., Zhang D.D. Acetylation of Nrf2 by p300/CBP augments promoter-specific DNA binding of Nrf2 during the antioxidant response. Mol. Cell. Biol. 2009;29:2658\u20132672. doi: 10.1128/MCB.01639-08.", "ArticleIdList": ["10.1128/MCB.01639-08", "PMC2682049", "19273602"]}, {"Citation": "Cuadrado A. Structural and functional characterization of Nrf2 degradation by glycogen synthase kinase 3/beta-TrCP. Free Radic. Biol. Med. 2015;88:147\u2013157. doi: 10.1016/j.freeradbiomed.2015.04.029.", "ArticleIdList": ["10.1016/j.freeradbiomed.2015.04.029", "25937177"]}, {"Citation": "Wang H., Liu K., Geng M., Gao P., Wu X., Hai Y., Li Y., Li Y., Luo L., Hayes J.D., Wang X.J., Tang X. RXRalpha inhibits the NRF2-ARE signaling pathway through a direct interaction with the Neh7 domain of NRF2. Cancer Res. 2013;73:3097\u20133108. doi: 10.1158/0008-5472.CAN-12-3386.", "ArticleIdList": ["10.1158/0008-5472.CAN-12-3386", "23612120"]}, {"Citation": "Canning P., Sorrell F.J., Bullock A.N. Structural basis of Keap1 interactions with Nrf2. Free Radic. Biol. Med. 2015;88:101\u2013107. doi: 10.1016/j.freeradbiomed.2015.05.034.", "ArticleIdList": ["10.1016/j.freeradbiomed.2015.05.034", "PMC4668279", "26057936"]}, {"Citation": "Jung B.J., Yoo H.S., Shin S., Park Y.J., Jeon S.M. Dysregulation of NRF2 in cancer: from molecular mechanisms to therapeutic opportunities. Biomol. Ther. (Seoul.) 2018;26:57\u201368. doi: 10.4062/biomolther.2017.195.", "ArticleIdList": ["10.4062/biomolther.2017.195", "PMC5746038", "29212307"]}, {"Citation": "Lo S.C., Hannink M. PGAM5 tethers a ternary complex containing Keap1 and Nrf2 to mitochondria. Exp. Cell Res. 2008;314:1789\u20131803. doi: 10.1016/j.yexcr.2008.02.014.", "ArticleIdList": ["10.1016/j.yexcr.2008.02.014", "PMC2409987", "18387606"]}, {"Citation": "Theodore M., Kawai Y., Yang J., Kleshchenko Y., Reddy S.P., Villalta F., Arinze I.J. Multiple nuclear localization signals function in the nuclear import of the transcription factor Nrf2. J. Biol. Chem. 2008;283:8984\u20138994. doi: 10.1074/jbc.M709040200.", "ArticleIdList": ["10.1074/jbc.M709040200", "PMC2276363", "18238777"]}, {"Citation": "Li W., Jain M.R., Chen C., Yue X., Hebbar V., Zhou R., Kong A.N. Nrf2 possesses a redox-insensitive nuclear export signal overlapping with the leucine zipper motif. J. Biol. Chem. 2005;280:28430\u201328438. doi: 10.1074/jbc.M410601200.", "ArticleIdList": ["10.1074/jbc.M410601200", "15917227"]}, {"Citation": "Li W., Yu S.W., Kong A.N. Nrf2 possesses a redox-sensitive nuclear exporting signal in the Neh5 transactivation domain. J. Biol. Chem. 2006;281:27251\u201327263. doi: 10.1074/jbc.M602746200.", "ArticleIdList": ["10.1074/jbc.M602746200", "16790425"]}, {"Citation": "Li W., Yu S., Liu T., Kim J.H., Blank V., Li H., Kong A.N. Heterodimerization with small maf proteins enhances nuclear retention of Nrf2 via masking the NESzip motif. Biochim. Biophys. Acta. 2008;1783:1847\u20131856. doi: 10.1016/j.bbamcr.2008.05.024.", "ArticleIdList": ["10.1016/j.bbamcr.2008.05.024", "PMC2570698", "18585411"]}, {"Citation": "Davudian S., Mansoori B., Shajari N., Mohammadi A., Baradaran B. BACH1, the master regulator gene: a novel candidate target for cancer therapy. Gene. 2016;588:30\u201337. doi: 10.1016/j.gene.2016.04.040.", "ArticleIdList": ["10.1016/j.gene.2016.04.040", "27108804"]}, {"Citation": "Dhakshinamoorthy S., Jain A.K., Bloom D.A., Jaiswal A.K. Bach1 competes with Nrf2 leading to negative regulation of the antioxidant response element (ARE)-mediated NAD(P)H:quinone oxidoreductase 1 gene expression and induction in response to antioxidants. J. Biol. Chem. 2005;280:16891\u201316900. doi: 10.1074/jbc.M500166200.", "ArticleIdList": ["10.1074/jbc.M500166200", "15734732"]}, {"Citation": "Jyrkkanen H.K., Kuosmanen S., Heinaniemi M., Laitinen H., Kansanen E., Mella-Aho E., Leinonen H., Yla-Herttuala S., Levonen A.L. Novel insights into the regulation of antioxidant-response-element-mediated gene expression by electrophiles: induction of the transcriptional repressor BACH1 by Nrf2. Biochem. J. 2011;440:167\u2013174. doi: 10.1042/BJ20110526.", "ArticleIdList": ["10.1042/BJ20110526", "21812759"]}, {"Citation": "Levy S., Forman H.J. C-myc is a Nrf2-interacting protein that negatively regulates phase II genes through their electrophile responsive elements. IUBMBLife. 2010;62:237\u2013246. doi: 10.1002/iub.314.", "ArticleIdList": ["10.1002/iub.314", "PMC2852429", "20232342"]}, {"Citation": "Guo Y., Yu S., Zhang C., Kong A.N. Epigenetic regulation of Keap1-Nrf2 signaling. Free Radic. Biol. Med. 2015;88:337\u2013349. doi: 10.1016/j.freeradbiomed.2015.06.013.", "ArticleIdList": ["10.1016/j.freeradbiomed.2015.06.013", "PMC4955581", "26117320"]}, {"Citation": "Hayes J.D., Chowdhry S., Dinkova-Kostova A.T., Sutherland C. Dual regulation of transcription factor Nrf2 by Keap1 and by the combined actions of beta-TrCP and GSK-3. Biochem. Soc. Trans. 2015;43:611\u2013620. doi: 10.1042/BST20150011.", "ArticleIdList": ["10.1042/BST20150011", "26551701"]}, {"Citation": "Krajka-Kuzniak V., Paluszczak J., Baer-Dubowska W. The Nrf2-ARE signaling pathway: an update on its regulation and possible role in cancer prevention and treatment. Pharmacol. Rep. 2017;69:393\u2013402. doi: 10.1016/j.pharep.2016.12.011.", "ArticleIdList": ["10.1016/j.pharep.2016.12.011", "28267640"]}, {"Citation": "Rojo D.L., Chapman V.E., Zhang D.D. NRF2 and the hallmarks of cancer. Cancer Cell. 2018;34:21\u201343. doi: 10.1016/j.ccell.2018.03.022.", "ArticleIdList": ["10.1016/j.ccell.2018.03.022", "PMC6039250", "29731393"]}, {"Citation": "Kobayashi M., Li L., Iwamoto N., Nakajima-Takagi Y., Kaneko H., Nakayama Y., Eguchi M., Wada Y., Kumagai Y., Yamamoto M. The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Mol. Cell. Biol. 2009;29:493\u2013502. doi: 10.1128/MCB.01080-08.", "ArticleIdList": ["10.1128/MCB.01080-08", "PMC2612520", "19001094"]}, {"Citation": "Yamamoto T., Suzuki T., Kobayashi A., Wakabayashi J., Maher J., Motohashi H., Yamamoto M. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol. Cell. Biol. 2008;28:2758\u20132770. doi: 10.1128/MCB.01704-07.", "ArticleIdList": ["10.1128/MCB.01704-07", "PMC2293100", "18268004"]}, {"Citation": "Tao S., Liu P., Luo G., Vega R.M., Chen H., Wu T., Tllotson J., Chapman E., Zhang D.D. p97 negatively regulates NRF2 by extracting ubiquitylated NRF2 from the KEAP1-CUL3 E3 complex. Mol. Cell. Biol. 2017;37 doi: 10.1128/MCB.00660-16.", "ArticleIdList": ["10.1128/MCB.00660-16", "PMC5376629", "28115426"]}, {"Citation": "Dinkova-Kostova A.T., Abramov A.Y. The emerging role of Nrf2 in mitochondrial function. Free Radic. Biol. Med. 2015;88:179\u2013188. doi: 10.1016/j.freeradbiomed.2015.04.036.", "ArticleIdList": ["10.1016/j.freeradbiomed.2015.04.036", "PMC4726722", "25975984"]}, {"Citation": "Baird L., Lleres D., Swift S., Dinkova-Kostova A.T. Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex. Proc. Natl. Acad. Sci. U. S. A. 2013;110:15259\u201315264. doi: 10.1073/pnas.1305687110.", "ArticleIdList": ["10.1073/pnas.1305687110", "PMC3780858", "23986495"]}, {"Citation": "Baird L., Swift S., Lleres D., Dinkova-Kostova A.T. Monitoring Keap1-Nrf2 interactions in single live cells. Biotechnol. Adv. 2014;32:1133\u20131144. doi: 10.1016/j.biotechadv.2014.03.004.", "ArticleIdList": ["10.1016/j.biotechadv.2014.03.004", "PMC4165437", "24681086"]}, {"Citation": "Iso T., Suzuki T., Baird L., Yamamoto M. Absolute amounts and status of the Nrf2-Keap1-Cul3 complex within cells. Mol. Cell. Biol. 2016;36:3100\u20133112. doi: 10.1128/MCB.00389-16.", "ArticleIdList": ["10.1128/MCB.00389-16", "PMC5126296", "27697860"]}, {"Citation": "Sun Z., Wu T., Zhao F., Lau A., Birch C.M., Zhang D.D. KPNA6 (Importin {alpha}7)-mediated nuclear import of Keap1 represses the Nrf2-dependent antioxidant response. Mol. Cell. Biol. 2011;31:1800\u20131811. doi: 10.1128/MCB.05036-11.", "ArticleIdList": ["10.1128/MCB.05036-11", "PMC3133232", "21383067"]}, {"Citation": "Sun Z., Zhang S., Chan J.Y., Zhang D.D. Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2. Mol. Cell. Biol. 2007;27:6334\u20136349.", "ArticleIdList": ["PMC2099624", "17636022"]}, {"Citation": "Velichkova M., Hasson T. Keap1 regulates the oxidation-sensitive shuttling of Nrf2 into and out of the nucleus via a Crm1-dependent nuclear export mechanism. Mol. Cell. Biol. 2005;25:4501\u20134513. doi: 10.1128/MCB.25.11.4501-4513.2005.", "ArticleIdList": ["10.1128/MCB.25.11.4501-4513.2005", "PMC1140621", "15899855"]}, {"Citation": "Karapetian R.N., Evstafieva A.G., Abaeva I.S., Chichkova N.V., Filonov G.S., Rubtsov Y.P., Sukhacheva E.A., Melnikov S.V., Schneider U., Wanker E.E., Vartapetian A.B. Nuclear oncoprotein prothymosin alpha is a partner of Keap1: implications for expression of oxidative stress-protecting genes. Mol. Cell. Biol. 2005;25:1089\u20131099. doi: 10.1128/MCB.25.3.1089-1099.2005.", "ArticleIdList": ["10.1128/MCB.25.3.1089-1099.2005", "PMC544000", "15657435"]}, {"Citation": "Kaspar J.W., Niture S.K., Jaiswal A.K. Nrf 2:INrf2 (Keap1) signaling in oxidative stress. Free Radic. Biol. Med. 2009;47:1304\u20131309. doi: 10.1016/j.freeradbiomed.2009.07.035.", "ArticleIdList": ["10.1016/j.freeradbiomed.2009.07.035", "PMC2763938", "19666107"]}, {"Citation": "Gordon L.B., Rothman F.G., Lopez-Otin C., Misteli T. Progeria: a paradigm for translational medicine. Cell. 2014;156:400\u2013407. doi: 10.1016/j.cell.2013.12.028.", "ArticleIdList": ["10.1016/j.cell.2013.12.028", "PMC6318797", "24485450"]}, {"Citation": "Gabriel D., Roedl D., Gordon L.B., Djabali K. Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts. Aging Cell. 2015;14:78\u201391. doi: 10.1111/acel.12300.", "ArticleIdList": ["10.1111/acel.12300", "PMC4326906", "25510262"]}, {"Citation": "Kubben N., Zhang W., Wang L., Voss T.C., Yang J., Qu J., Liu G.H., Misteli T. Repression of the antioxidant NRF2 pathway in premature aging. Cell. 2016;165:1361\u20131374. doi: 10.1016/j.cell.2016.05.017.", "ArticleIdList": ["10.1016/j.cell.2016.05.017", "PMC4893198", "27259148"]}, {"Citation": "Silva-Palacios A., Ostolga-Chavarria M., Zazueta C., Konigsberg M. Nrf2: molecular and epigenetic regulation during aging. Ageing Res. Rev. 2018;47:31\u201340. doi: 10.1016/j.arr.2018.06.003.", "ArticleIdList": ["10.1016/j.arr.2018.06.003", "29913211"]}, {"Citation": "Yu C., Xiao J.H. The Keap1-Nrf2 system: a mediator between oxidative stress and aging. Oxidative Med. Cell. Longev. 2021 doi: 10.1155/2021/6635460.", "ArticleIdList": ["10.1155/2021/6635460", "PMC8106771", "34012501"]}, {"Citation": "Lewis K.N., Wason E., Edrey Y.H., Kristan D.M., Nevo E., Buffenstein R. Regulation of Nrf2 signaling and longevity in naturally long-lived rodents. Proc. Natl. Acad. Sci. U. S. A. 2015;112:3722\u20133727. doi: 10.1073/pnas.1417566112.", "ArticleIdList": ["10.1073/pnas.1417566112", "PMC4378420", "25775529"]}, {"Citation": "Biggin M.D. Animal transcription networks as highly connected, quantitative continua. Dev. Cell. 2011;21:611\u2013626. doi: 10.1016/j.devcel.2011.09.008.", "ArticleIdList": ["10.1016/j.devcel.2011.09.008", "22014521"]}, {"Citation": "Itoh K., Wakabayashi N., Katoh Y., Ishii T., O'Connor T., Yamamoto M. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells. 2003;8:379\u2013391. doi: 10.1046/j.1365-2443.2003.00640.x.", "ArticleIdList": ["10.1046/j.1365-2443.2003.00640.x", "12653965"]}, {"Citation": "Kobayashi A., Kang M.I., Okawa H., Ohtsuji M., Zenke Y., Chiba T., Igarashi K., Yamamoto M. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell. Biol. 2004;24:7130\u20137139. (1128/MCB.24.16.7130-7139.2004)", "ArticleIdList": ["PMC479737", "15282312"]}, {"Citation": "Nguyen T., Sherratt P.J., Huang H.C., Yang C.S., Pickett C.B. Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element. Degradation of Nrf2 by the 26 S proteasome. J. Biol. Chem. 2003;278:4536\u20134541. doi: 10.1074/jbc.M207293200.", "ArticleIdList": ["10.1074/jbc.M207293200", "12446695"]}, {"Citation": "Stewart D., Killeen E., Naquin R., Alam S., Alam J. Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. J. Biol. Chem. 2003;278:2396\u20132402. doi: 10.1074/jbc.M209195200.", "ArticleIdList": ["10.1074/jbc.M209195200", "12441344"]}, {"Citation": "Taguchi K., Fujikawa N., Komatsu M., Ishii T., Unno M., Akaike T., Motohashi H., Yamamoto M. Keap1 degradation by autophagy for the maintenance of redox homeostasis. Proc. Natl. Acad. Sci. U. S. A. 2012;109:13561\u201313566. doi: 10.1073/pnas.1121572109.", "ArticleIdList": ["10.1073/pnas.1121572109", "PMC3427110", "22872865"]}, {"Citation": "Niture S.K., Jaiswal A.K. INrf2 (Keap1) targets Bcl-2 degradation and controls cellular apoptosis. Cell Death Differ. 2011;18:439\u2013451. doi: 10.1038/cdd.2010.114.", "ArticleIdList": ["10.1038/cdd.2010.114", "PMC3010499", "20865015"]}, {"Citation": "Kim J.E., You D.J., Lee C., Ahn C., Seong J.Y., Hwang J.I. Suppression of NF-kappaB signaling by KEAP1 regulation of IKKbeta activity through autophagic degradation and inhibition of phosphorylation. Cell. Signal. 2010;22:1645\u20131654. doi: 10.1016/j.cellsig.2010.06.004.", "ArticleIdList": ["10.1016/j.cellsig.2010.06.004", "20600852"]}, {"Citation": "Silva-Islas C.A., Maldonado P.D. Canonical and non-canonical mechanisms of Nrf2 activation. Pharmacol. Res. 2018;134:92\u201399. doi: 10.1016/j.phrs.2018.06.013.", "ArticleIdList": ["10.1016/j.phrs.2018.06.013", "29913224"]}, {"Citation": "Kopacz A., Kloska D., Forman H.J., Jozkowicz A., Grochot-Przeczek A. Beyond repression of Nrf2: an update on Keap1. Free Radic. Biol. Med. 2020;157:63\u201374. doi: 10.1016/j.freeradbiomed.2020.03.023.", "ArticleIdList": ["10.1016/j.freeradbiomed.2020.03.023", "PMC7732858", "32234331"]}, {"Citation": "Karttunen M., Choy W.Y., Cino E.A. Prediction of binding energy of Keap1 interaction motifs in the Nrf2 antioxidant pathway and design of potential high-affinity peptides. J. Phys. Chem. B. 2018;122:5851\u20135859. doi: 10.1021/acs.jpcb.8b03295.", "ArticleIdList": ["10.1021/acs.jpcb.8b03295", "29745220"]}, {"Citation": "Dodson M., Zhang D.D. Non-canonical activation of NRF2: new insights and its relevance to disease. Curr. Pathobiol. Rep. 2017;5:171\u2013176. doi: 10.1007/s40139-017-0131-0.", "ArticleIdList": ["10.1007/s40139-017-0131-0", "PMC5654572", "29082113"]}, {"Citation": "Ichimura Y., Waguri S., Sou Y.S., Kageyama S., Hasegawa J., Ishimura R., Saito T., Yang Y., Kouno T., Fukutomi T., Hoshii T., Hirao A., Takagi K., Mizushima T., Motohashi H., Lee M.S., Yoshimori T., Tanaka K., Yamamoto M., Komatsu M. Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol. Cell. 2013;51:618\u2013631. doi: 10.1016/j.molcel.2013.08.003.", "ArticleIdList": ["10.1016/j.molcel.2013.08.003", "24011591"]}, {"Citation": "Komatsu M., Kurokawa H., Waguri S., Taguchi K., Kobayashi A., Ichimura Y., Sou Y.S., Ueno I., Sakamoto A., Tong K.I., Kim M., Nishito Y., Iemura S., Natsume T., Ueno T., Kominami E., Motohashi H., Tanaka K., Yamamoto M. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat. Cell Biol. 2010;12:213\u2013223. doi: 10.1038/ncb2021.", "ArticleIdList": ["10.1038/ncb2021", "20173742"]}, {"Citation": "Chen W., Sun Z., Wang X.J., Jiang T., Huang Z., Fang D., Zhang D.D. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol. Cell. 2009;34:663\u2013673. doi: 10.1016/j.molcel.2009.04.029.", "ArticleIdList": ["10.1016/j.molcel.2009.04.029", "PMC2714804", "19560419"]}, {"Citation": "El-Deiry W.S. p21(WAF1) mediates cell-cycle inhibition, relevant to cancer suppression and therapy. Cancer Res. 2016;76:5189\u20135191. doi: 10.1158/0008-5472.CAN-16-2055.", "ArticleIdList": ["10.1158/0008-5472.CAN-16-2055", "PMC5028108", "27635040"]}, {"Citation": "Karimian A., Ahmadi Y., Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst) 2016;42:63\u201371. doi: 10.1016/j.dnarep.2016.04.008.", "ArticleIdList": ["10.1016/j.dnarep.2016.04.008", "27156098"]}, {"Citation": "Lau A., Wang X.J., Zhao F., Villeneuve N.F., Wu T., Jiang T., Sun Z., White E., Zhang D.D. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol. Cell. Biol. 2010;30:3275\u20133285. doi: 10.1128/MCB.00248-10.", "ArticleIdList": ["10.1128/MCB.00248-10", "PMC2897585", "20421418"]}, {"Citation": "Padmanabhan B., Nakamura Y., Yokoyama S. Structural analysis of the complex of Keap1 with a prothymosin alpha peptide. Acta Crystallogr.Sect. F. Struct. Biol. Cryst. Commun. 2008;64:233\u2013238. doi: 10.1107/S1744309108004995.", "ArticleIdList": ["10.1107/S1744309108004995", "PMC2374262", "18391415"]}, {"Citation": "Hast B.E., Goldfarb D., Mulvaney K.M., Hast M.A., Siesser P.F., Yan F., Hayes D.N., Major M.B. Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination. Cancer Res. 2013;73:2199\u20132210.", "ArticleIdList": ["PMC3618590", "23382044"]}, {"Citation": "Lu K., Alcivar A.L., Ma J., Foo T.K., Zywea S., Mahdi A., Huo Y., Kensler T.W., Gatza M.L., Xia B. NRF2 induction supporting breast cancer cell survival is enabled by oxidative stress-induced DPP3-KEAP1 interaction. Cancer Res. 2017;77:2881\u20132892. doi: 10.1158/0008-5472.CAN-16-2204.", "ArticleIdList": ["10.1158/0008-5472.CAN-16-2204", "PMC5464605", "28416489"]}, {"Citation": "Camp N.D., James R.G., Dawson D.W., Yan F., Davison J.M., Houck S.A., Tang X., Zheng N., Major M.B., Moon R.T. Wilms tumor gene on X chromosome (WTX) inhibits degradation of NRF2 protein through competitive binding to KEAP1 protein. J. Biol. Chem. 2012;287:6539\u20136550. doi: 10.1074/jbc.M111.316471.", "ArticleIdList": ["10.1074/jbc.M111.316471", "PMC3307315", "22215675"]}, {"Citation": "Ma J., Cai H., Wu T., Sobhian B., Huo Y., Alcivar A., Mehta M., Cheung K.L., Ganesan S., Kong A.N., Zhang D.D., Xia B. PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function. Mol. Cell. Biol. 2012;32:1506\u20131517. doi: 10.1128/MCB.06271-11.", "ArticleIdList": ["10.1128/MCB.06271-11", "PMC3318596", "22331464"]}, {"Citation": "Ge W., Zhao K., Wang X., Li H., Yu M., He M., Xue X., Zhu Y., Zhang C., Cheng Y., Jiang S., Hu Y. iASPP is an antioxidative factor and drives cancer growth and drug resistance by competing with Nrf2 for Keap1 binding. Cancer Cell. 2017;32:561\u2013573. doi: 10.1016/j.ccell.2017.09.008.", "ArticleIdList": ["10.1016/j.ccell.2017.09.008", "29033244"]}, {"Citation": "Wang Q., Ma J., Lu Y., Zhang S., Huang J., Chen J., Bei J.X., Yang K., Wu G., Huang K., Chen J., Xu S. CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells. Oncogene. 2017;36:5321\u20135330. doi: 10.1038/onc.2017.161.", "ArticleIdList": ["10.1038/onc.2017.161", "28534518"]}, {"Citation": "Yang C., Tan Y.X., Yang G.Z., Zhang J., Pan Y.F., Liu C., Fu J., Chen Y., Ding Z.W., Dong L.W., Wang H.Y. Gankyrin has an antioxidative role through the feedback regulation of Nrf2 in hepatocellular carcinoma. J. Exp. Med. 2016;213:859\u2013875. doi: 10.1084/jem.20151208.", "ArticleIdList": ["10.1084/jem.20151208", "PMC4854728", "27091842"]}, {"Citation": "Zhou X.L., Zhu C.Y., Wu Z.G., Guo X., Zou W. The oncoprotein HBXIP competitively binds KEAP1 to activate NRF2 and enhance breast cancer cell growth and metastasis. Oncogene. 2019;38:4028\u20134046. doi: 10.1038/s41388-019-0698-5.", "ArticleIdList": ["10.1038/s41388-019-0698-5", "30692632"]}, {"Citation": "Mulvaney K.M., Matson J.P., Siesser P.F., Tamir T.Y., Goldfarb D., Jacobs T.M., Cloer E.W., Harrison J.S., Vaziri C., Cook J.G., Major M.B. Identification and characterization of MCM3 as a kelch-like ECH-associated protein 1 (KEAP1) substrate. J. Biol. Chem. 2016;291:23719\u201323733. doi: 10.1074/jbc.M116.729418.", "ArticleIdList": ["10.1074/jbc.M116.729418", "PMC5095425", "27621311"]}, {"Citation": "Cheng K.C., Lin R.J., Cheng J.Y., Wang S.H., Yu J.C., Wu J.C., Liang Y.J., Hsu H.M., Yu J., Yu A.L. FAM129B, an antioxidative protein, reduces chemosensitivity by competing with Nrf2 for Keap1 binding. EBioMedicine. 2019;45:25\u201338. doi: 10.1016/j.ebiom.2019.06.022.", "ArticleIdList": ["10.1016/j.ebiom.2019.06.022", "PMC6642435", "31262713"]}, {"Citation": "Wan Z.H., Jiang T.Y., Shi Y.Y., Pan Y.F., Lin Y.K., Ma Y.H., Yang C., Feng X.F., Huang L.F., Kong X.N., Ding Z.W., Tan Y.X., Dong L.W., Wang H.Y. RPB5-mediating protein promotes cholangiocarcinoma tumorigenesis and drug resistance by competing with NRF2 for KEAP1 binding. Hepatology. 2020;71:2005\u20132022. doi: 10.1002/hep.30962.", "ArticleIdList": ["10.1002/hep.30962", "31541481"]}, {"Citation": "Hirotsu Y., Katsuoka F., Funayama R., Nagashima T., Nishida Y., Nakayama K., Engel J.D., Yamamoto M. Nrf2-MafG heterodimers contribute globally to antioxidant and metabolic networks. Nucleic Acids Res. 2012;40:10228\u201310239. doi: 10.1093/nar/gks827.", "ArticleIdList": ["10.1093/nar/gks827", "PMC3488259", "22965115"]}, {"Citation": "Chorley B.N., Campbell M.R., Wang X., Karaca M., Sambandan D., Bangura F., Xue P., Pi J., Kleeberger S.R., Bell D.A. Identification of novel NRF2-regulated genes by ChIP-seq: influence on retinoid X receptor alpha. Nucleic Acids Res. 2012;40:7416\u20137429. doi: 10.1093/nar/gks409.", "ArticleIdList": ["10.1093/nar/gks409", "PMC3424561", "22581777"]}, {"Citation": "Hou Y., Xue P., Bai Y., Liu D., Woods C.G., Yarborough K., Fu J., Zhang Q., Sun G., Collins S., Chan J.Y., Yamamoto M., Andersen M.E., Pi J. Nuclear factor erythroid-derived factor 2-related factor 2 regulates transcription of CCAAT/enhancer-binding protein beta during adipogenesis. Free Radic. Biol. Med. 2012;52:462\u2013472. doi: 10.1016/j.freeradbiomed.2011.10.453.", "ArticleIdList": ["10.1016/j.freeradbiomed.2011.10.453", "PMC3307524", "22138520"]}, {"Citation": "Shin S., Wakabayashi N., Misra V., Biswal S., Lee G.H., Agoston E.S., Yamamoto M., Kensler T.W. NRF2 modulates aryl hydrocarbon receptor signaling: influence on adipogenesis. Mol. Cell. Biol. 2007;27:7188\u20137197. doi: 10.1128/MCB.00915-07.", "ArticleIdList": ["10.1128/MCB.00915-07", "PMC2168916", "17709388"]}, {"Citation": "Malhotra D., Portales-Casamar E., Singh A., Srivastava S., Arenillas D., Happel C., Shyr C., Wakabayashi N., Kensler T.W., Wasserman W.W., Biswal S. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-seq profiling and network analysis. Nucleic Acids Res. 2010;38:5718\u20135734. doi: 10.1093/nar/gkq212.", "ArticleIdList": ["10.1093/nar/gkq212", "PMC2943601", "20460467"]}, {"Citation": "Wakabayashi N., Shin S., Slocum S.L., Agoston E.S., Wakabayashi J., Kwak M.K., Misra V., Biswal S., Yamamoto M., Kensler T.W. Regulation of notch1 signaling by nrf2: implications for tissue regeneration. Sci. Signal. 2010;3 doi: 10.1126/scisignal.2000762.", "ArticleIdList": ["10.1126/scisignal.2000762", "PMC2932745", "20628156"]}, {"Citation": "Niture S.K., Jaiswal A.K. Hsp90 interaction with INrf2(Keap1) mediates stress-induced Nrf2 activation. J. Biol. Chem. 2010;285:36865\u201336875. doi: 10.1074/jbc.M110.175802.", "ArticleIdList": ["10.1074/jbc.M110.175802", "PMC2978616", "20864537"]}, {"Citation": "Lee D.F., Kuo H.P., Liu M., Chou C.K., Xia W., Du Y., Shen J., Chen C.T., Huo L., Hsu M.C., Li C.W., Ding Q., Liao T.L., Lai C.C., Lin A.C., Chang Y.H., Tsai S.F., Li L.Y., Hung M.C. KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol. Cell. 2009;36:131\u2013140. doi: 10.1016/j.molcel.2009.07.025.", "ArticleIdList": ["10.1016/j.molcel.2009.07.025", "PMC2770835", "19818716"]}, {"Citation": "You A., Nam C.W., Wakabayashi N., Yamamoto M., Kensler T.W., Kwak M.K. Transcription factor Nrf2 maintains the basal expression of Mdm2: an implication of the regulation of p53 signaling by Nrf2. Arch. Biochem. Biophys. 2011;507:356\u2013364. doi: 10.1016/j.abb.2010.12.034.", "ArticleIdList": ["10.1016/j.abb.2010.12.034", "21211512"]}, {"Citation": "Johnson D.A., Johnson J.A. Nrf2\u2013a therapeutic target for the treatment of neurodegenerative diseases. Free Radic. Biol. Med. 2015;88:253\u2013267. doi: 10.1016/j.freeradbiomed.2015.07.147.", "ArticleIdList": ["10.1016/j.freeradbiomed.2015.07.147", "PMC4809057", "26281945"]}, {"Citation": "Smith R.E., Tran K., Smith C.C., McDonald M., Shejwalkar P., Hara K. The role of the Nrf2/ARE antioxidant system in preventing cardiovascular diseases. Diseases. 2016;4 doi: 10.3390/diseases4040034.", "ArticleIdList": ["10.3390/diseases4040034", "PMC5456329", "28933413"]}, {"Citation": "Alfieri A., Srivastava S., Siow R.C., Modo M., Fraser P.A., Mann G.E. Targeting the Nrf2-Keap1 antioxidant defence pathway for neurovascular protection in stroke. J. Physiol. 2011;589:4125\u20134136. doi: 10.1113/jphysiol.2011.210294.", "ArticleIdList": ["10.1113/jphysiol.2011.210294", "PMC3180573", "21646410"]}, {"Citation": "Chen Q.M., Maltagliati A.J. Nrf2 at the heart of oxidative stress and cardiac protection. Physiol. Genomics. 2018;50:77\u201397. doi: 10.1152/physiolgenomics.00041.2017.", "ArticleIdList": ["10.1152/physiolgenomics.00041.2017", "PMC5867612", "29187515"]}, {"Citation": "Ferrandiz M.L., Nacher-Juan J., Alcaraz M.J. Nrf2 as a therapeutic target for rheumatic diseases. Biochem. Pharmacol. 2018;152:338\u2013346. doi: 10.1016/j.bcp.2018.04.010.", "ArticleIdList": ["10.1016/j.bcp.2018.04.010", "29660314"]}, {"Citation": "Cuadrado A., Manda G., Hassan A., Alcaraz M.J., Barbas C., Daiber A., Ghezzi P., Leon R., Lopez M.G., Oliva B., Pajares M., Rojo A.I., Robledinos-Anton N., Valverde A.M., Guney E., Schmidt H.H.H.W. Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach. Pharmacol. Rev. 2018;70:348\u2013383. doi: 10.1124/pr.117.014753.", "ArticleIdList": ["10.1124/pr.117.014753", "29507103"]}, {"Citation": "Paracha U.Z., Fatima K., Alqahtani M., Chaudhary A., Abuzenadah A., Damanhouri G., Qadri I. Oxidative stress and hepatitis C virus. Virol. J. 2013;10:251. doi: 10.1186/1743-422X-10-251.", "ArticleIdList": ["10.1186/1743-422X-10-251", "PMC3751576", "23923986"]}, {"Citation": "Ivanov A.V., Valuev-Elliston V.T., Ivanova O.N., Kochetkov S.N., Starodubova E.S., Bartosch B., Isaguliants M.G. Oxidative stress during HIV infection: mechanisms and consequences. Oxid. Med. Cell Longev. 2016 doi: 10.1155/2016/8910396.", "ArticleIdList": ["10.1155/2016/8910396", "PMC5088339", "27829986"]}, {"Citation": "Delgado-Roche L., Mesta F. Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-CoV) infection. Arch. Med. Res. 2020;51:384\u2013387. doi: 10.1016/j.arcmed.2020.04.019.", "ArticleIdList": ["10.1016/j.arcmed.2020.04.019", "PMC7190501", "32402576"]}, {"Citation": "Wang Q., Li W.X., Dai S.X., Guo Y.C., Han F.F., Zheng J.J., Li G.H., Huang J.F. Meta-analysis of Parkinson's disease and Alzheimer's disease revealed commonly impaired pathways and dysregulation of NRF2-dependent genes. J. Alzheimers Dis. 2017;56:1525\u20131539. doi: 10.3233/JAD-161032.", "ArticleIdList": ["10.3233/JAD-161032", "28222515"]}, {"Citation": "von Otter M., Landgren S., Nilsson S., Celojevic D., Bergstrom P., Hakansson A., Nissbrandt H., Drozdzik M., Bialecka M., Kurzawski M., Blennow K., Nilsson M., Hammarsten O., Zetterberg H. Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease. BMC Med. Genet. 2010;11:36. doi: 10.1186/1471-2350-11-36.", "ArticleIdList": ["10.1186/1471-2350-11-36", "PMC2843602", "20196834"]}, {"Citation": "Gui Y., Zhang L., Lv W., Zhang W., Zhao J., Hu X. NFE2L2 variations reduce antioxidant response in patients with parkinson disease. Oncotarget. 2016;7:10756\u201310764. doi: 10.18632/oncotarget.7353.", "ArticleIdList": ["10.18632/oncotarget.7353", "PMC4905436", "26887053"]}, {"Citation": "von Otter M., Bergstrom P., Quattrone A., De Marco E.V., Annesi G., Soderkvist P., Wettinger S.B., Drozdzik M., Bialecka M., Nissbrandt H., Klein C., Nilsson M., Hammarsten O., Nilsson S., Zetterberg H. Genetic associations of Nrf2-encoding NFE2L2 variants with Parkinson's disease - a multicenter study. BMC Med. Genet. 2014;15:131. doi: 10.1186/s12881-014-0131-4.", "ArticleIdList": ["10.1186/s12881-014-0131-4", "PMC4335439", "25496089"]}, {"Citation": "von Otter M., Landgren S., Nilsson S., Zetterberg M., Celojevic D., Bergstrom P., Minthon L., Bogdanovic N., Andreasen N., Gustafson D.R., Skoog I., Wallin A., Tasa G., Blennow K., Nilsson M., Hammarsten O., Zetterberg H. Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract. Mech. Ageing Dev. 2010;131:105\u2013110. doi: 10.1016/j.mad.2009.12.007.", "ArticleIdList": ["10.1016/j.mad.2009.12.007", "20064547"]}, {"Citation": "Bergstrom P., Von O.M., Nilsson S., Nilsson A.C., Nilsson M., Andersen P.M., Hammarsten O., Zetterberg H. Association of NFE2L2 and KEAP1 haplotypes with amyotrophic lateral sclerosis. Amyotroph. Lateral. Scler. Frontotemporal. Degener. 2014;15:130\u2013137. doi: 10.3109/21678421.2013.839708.", "ArticleIdList": ["10.3109/21678421.2013.839708", "24102512"]}, {"Citation": "Arisawa T., Tahara T., Shibata T., Nagasaka M., Nakamura M., Kamiya Y., Fujita H., Yoshioka D., Okubo M., Sakata M., Wang F.Y., Hirata I., Nakano H. Nrf2 gene promoter polymorphism is associated with ulcerative colitis in a japanese population. Hepato-Gastroenterology. 2008;55:394\u2013397.", "ArticleIdList": ["18613373"]}, {"Citation": "Burton N.C., Kensler T.W., Guilarte T.R. In vivo modulation of the parkinsonian phenotype by Nrf2. Neurotoxicology. 2006;27:1094\u20131100. doi: 10.1016/j.neuro.2006.07.019.", "ArticleIdList": ["10.1016/j.neuro.2006.07.019", "16959318"]}, {"Citation": "Chen P.C., Vargas M.R., Pani A.K., Smeyne R.J., Johnson D.A., Kan Y.W., Johnson J.A. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc. Natl. Acad. Sci. U. S. A. 2009;106:2933\u20132938. doi: 10.1073/pnas.0813361106.", "ArticleIdList": ["10.1073/pnas.0813361106", "PMC2650368", "19196989"]}, {"Citation": "Jazwa A., Rojo A.I., Innamorato N.G., Hesse M., Fernandez-Ruiz J., Cuadrado A. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid. Redox.Signal. 2011;14:2347\u20132360. doi: 10.1089/ars.2010.3731.", "ArticleIdList": ["10.1089/ars.2010.3731", "21254817"]}, {"Citation": "Williamson T.P., Johnson D.A., Johnson J.A. Activation of the Nrf2-ARE pathway by siRNA knockdown of Keap1 reduces oxidative stress and provides partial protection from MPTP-mediated neurotoxicity. Neurotoxicology. 2012;33:272\u2013279. doi: 10.1016/j.neuro.2012.01.015.", "ArticleIdList": ["10.1016/j.neuro.2012.01.015", "PMC3521526", "22342405"]}, {"Citation": "Ramsey C.P., Glass C.A., Montgomery M.B., Lindl K.A., Ritson G.P., Chia L.A., Hamilton R.L., Chu C.T., Jordan-Sciutto K.L. Expression of Nrf2 in neurodegenerative diseases. J. Neuropathol. Exp. Neurol. 2007;66:75\u201385. doi: 10.1097/nen.0b013e31802d6da9.", "ArticleIdList": ["10.1097/nen.0b013e31802d6da9", "PMC2253896", "17204939"]}, {"Citation": "Kanninen K., Heikkinen R., Malm T., Rolova T., Kuhmonen S., Leinonen H., Yla-Herttuala S., Tanila H., Levonen A.L., Koistinaho M., Koistinaho J. Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2009;106:16505\u201316510. doi: 10.1073/pnas.0908397106.", "ArticleIdList": ["10.1073/pnas.0908397106", "PMC2752553", "19805328"]}, {"Citation": "Farr S.A., Ripley J.L., Sultana R., Zhang Z., Niehoff M.L., Platt T.L., Murphy M.P., Morley J.E., Kumar V., Butterfield D.A. Antisense oligonucleotide against GSK-3beta in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: involvement of transcription factor Nrf2 and implications for alzheimer disease. Free Radic. Biol. Med. 2014;67:387\u2013395. doi: 10.1016/j.freeradbiomed.2013.11.014.", "ArticleIdList": ["10.1016/j.freeradbiomed.2013.11.014", "PMC3945161", "24355211"]}, {"Citation": "Goven D., Boutten A., Lecon-Malas V., Marchal-Somme J., Amara N., Crestani B., Fournier M., Leseche G., Soler P., Boczkowski J., Bonay M. Altered Nrf2/Keap1-Bach1 equilibrium in pulmonary emphysema. Thorax. 2008;63:916\u2013924. doi: 10.1136/thx.2007.091181.", "ArticleIdList": ["10.1136/thx.2007.091181", "18559366"]}, {"Citation": "Suzuki M., Betsuyaku T., Ito Y., Nagai K., Nasuhara Y., Kaga K., Kondo S., Nishimura M. Down-regulated NF-E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 2008;39:673\u2013682. doi: 10.1165/rcmb.2007-0424OC.", "ArticleIdList": ["10.1165/rcmb.2007-0424OC", "18566336"]}, {"Citation": "Harvey C.J., Thimmulappa R.K., Sethi S., Kong X., Yarmus L., Brown R.H., Feller-Kopman D., Wise R., Biswal S. 2011;3", "ArticleIdList": ["PMC4927975", "21490276"]}, {"Citation": "Harvey C.J., Thimmulappa R.K., Sethi S., Kong X., Yarmus L., Brown R.H., Feller-Kopman D., Wise R., Biswal S. 2011;3", "ArticleIdList": ["PMC4927975", "21490276"]}, {"Citation": "Lu M.C., Ji J.A., Jiang Z.Y., You Q.D. The Keap1-Nrf2-ARE pathway as a potential preventive and therapeutic target: an update. Med. Res. Rev. 2016;36:924\u2013963. doi: 10.1002/med.21396.", "ArticleIdList": ["10.1002/med.21396", "27192495"]}, {"Citation": "Neymotin A., Calingasan N.Y., Wille E., Naseri N., Petri S., Damiano M., Liby K.T., Risingsong R., Sporn M., Beal M.F., Kiaei M. Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2011;51:88\u201396. doi: 10.1016/j.freeradbiomed.2011.03.027.", "ArticleIdList": ["10.1016/j.freeradbiomed.2011.03.027", "PMC3109235", "21457778"]}, {"Citation": "Todorovic M., Mellick G.D. 2016. Nrf2 and Parkinson's Disease.", "ArticleIdList": ["10.5772/65450"]}, {"Citation": "Buendia I., Michalska P., Navarro E., Gameiro I., Egea J., Leon R. Nrf2-ARE pathway: an emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases. Pharmacol. Ther. 2016;157:84\u2013104. doi: 10.1016/j.pharmthera.2015.11.003.", "ArticleIdList": ["10.1016/j.pharmthera.2015.11.003", "26617217"]}, {"Citation": "Dinkova-Kostova A.T., Kostov R.V., Kazantsev A.G. The role of Nrf2 signaling in counteracting neurodegenerative diseases. FEBS J. 2018;285:3576\u20133590. doi: 10.1111/febs.14379.", "ArticleIdList": ["10.1111/febs.14379", "PMC6221096", "29323772"]}, {"Citation": "Joshi G., Johnson J.A. The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat. CNS Drug. Discov. 2012;7:218\u2013229. doi: 10.2174/157488912803252023.", "ArticleIdList": ["10.2174/157488912803252023", "PMC3625035", "22742419"]}, {"Citation": "Niu Y., Zhang J., Dong M. Nrf2 as a potential target for Parkinson's disease therapy. J. Mol. Med. (Berl) 2021;99:917\u2013931. doi: 10.1007/s00109-021-02071-5.", "ArticleIdList": ["10.1007/s00109-021-02071-5", "33844027"]}, {"Citation": "Lee C. Therapeutic modulation of virus-induced oxidative stress via the Nrf2-dependent antioxidative pathway. Oxidative Med. Cell. Longev. 2018;2018:6208067. doi: 10.1155/2018/6208067.", "ArticleIdList": ["10.1155/2018/6208067", "PMC6234444", "30515256"]}, {"Citation": "Ramezani A., Nahad M.P., Faghihloo E. The role of Nrf2 transcription factor in viral infection. J. Cell. Biochem. 2018;119:6366\u20136382. doi: 10.1002/jcb.26897.", "ArticleIdList": ["10.1002/jcb.26897", "29737559"]}, {"Citation": "Herengt A., Thyrsted J., Holm C.K. NRF2 in viral infection. Antioxidants. (Basel) 2021;10:1491. doi: 10.3390/antiox10091491.", "ArticleIdList": ["10.3390/antiox10091491", "PMC8472116", "34573123"]}, {"Citation": "Kosmider B., Messier E.M., Janssen W.J., Nahreini P., Wang J., Hartshorn K.L., Mason R.J. Nrf2 protects human alveolar epithelial cells against injury induced by influenza A virus. Respir. Res. 2012;13:43. doi: 10.1186/1465-9921-13-43.", "ArticleIdList": ["10.1186/1465-9921-13-43", "PMC3520784", "22672594"]}, {"Citation": "Russell A.B., Trapnell C., Bloom J.D. Extreme heterogeneity of influenza virus infection in single cells. elife. 2018;7 doi: 10.7554/eLife.32303.", "ArticleIdList": ["10.7554/eLife.32303", "PMC5826275", "29451492"]}, {"Citation": "Cheng Y.L., Lin Y.S., Chen C.L., Tsai T.T., Tsai C.C., Wu Y.W., Ou Y.D., Chu Y.Y., Wang J.M., Yu C.Y., Lin C.F. Activation of Nrf2 by the dengue virus causes an increase in CLEC5A, which enhances TNF-alpha production by mononuclear phagocytes. Sci Rep. 2016;6:32000. doi: 10.1038/srep32000.", "ArticleIdList": ["10.1038/srep32000", "PMC4999957", "27561946"]}, {"Citation": "Ferrari M., Zevini A., Palermo E., Muscolini M., Alexandridi M., Etna M.P., Coccia E.M., Fernandez-Sesma A., Coyne C., Zhang D.D., Marques E.T.A., Olagnier D., Hiscott J. Dengue Virus Targets Nrf2 for NS2B3-Mediated Degradation Leading to Enhanced Oxidative Stress and Viral Replication. J. Virol. 2020;94", "ArticleIdList": ["PMC7925186", "32999020"]}, {"Citation": "Komaravelli N., Tian B., Ivanciuc T., Mautemps N., Brasier A.R., Garofalo R.P., Casola A. Respiratory syncytial virus infection down-regulates antioxidant enzyme expression by triggering deacetylation-proteasomal degradation of Nrf2. Free Radic. Biol. Med. 2015;88:391\u2013403. doi: 10.1016/j.freeradbiomed.2015.05.043.", "ArticleIdList": ["10.1016/j.freeradbiomed.2015.05.043", "PMC4628892", "26073125"]}, {"Citation": "Komaravelli N., Ansar M., Garofalo R.P., Casola A. Respiratory syncytial virus induces NRF2 degradation through a promyelocytic leukemia protein - ring finger protein 4 dependent pathway. Free Radic. Biol. Med. 2017;113:494\u2013504. doi: 10.1016/j.freeradbiomed.2017.10.380.", "ArticleIdList": ["10.1016/j.freeradbiomed.2017.10.380", "PMC5699968", "29107745"]}, {"Citation": "Cho H.Y., Imani F., Miller-DeGraff L., Walters D., Melendi G.A., Yamamoto M., Polack F.P., Kleeberger S.R. Antiviral activity of Nrf2 in a murine model of respiratory syncytial virus disease. Am. J. Respir. Crit. Care Med. 2009;179:138\u2013150. doi: 10.1164/rccm.200804-535OC.", "ArticleIdList": ["10.1164/rccm.200804-535OC", "PMC2633060", "18931336"]}, {"Citation": "Patra U., Mukhopadhyay U., Sarkar R., Mukherjee A., Chawla-Sarkar M. RA-839, a selective agonist of Nrf2/ARE pathway, exerts potent anti-rotaviral efficacy in vitro. Antivir. Res. 2019;161:53\u201362. doi: 10.1016/j.antiviral.2018.11.009.", "ArticleIdList": ["10.1016/j.antiviral.2018.11.009", "30465784"]}, {"Citation": "Wyler E., Franke V., Menegatti J., Kocks C., Boltengagen A., Praktiknjo S., Walch-Ruckheim B., Bosse J., Rajewsky N., Grasser F., Akalin A., Landthaler M. Single-cell RNA-sequencing of herpes simplex virus 1-infected cells connects NRF2 activation to an antiviral program. Nat. Commun. 2019;10:4878.", "ArticleIdList": ["PMC6814756", "31653857"]}, {"Citation": "Bender D., Hildt E. Effect of hepatitis viruses on the Nrf2/Keap1-signaling pathway and its impact on viral replication and pathogenesis. Int. J. Mol. Sci. 2019;20 doi: 10.3390/ijms20184659.", "ArticleIdList": ["10.3390/ijms20184659", "PMC6769940", "31546975"]}, {"Citation": "Cecchini R., Cecchini A.L. SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression. Med. Hypotheses. 2020;143 doi: 10.1016/j.mehy.2020.110102.", "ArticleIdList": ["10.1016/j.mehy.2020.110102", "PMC7357498", "32721799"]}, {"Citation": "Suhail S., Zajac J., Fossum C., Lowater H., McCracken C., Severson N., Laatsch B., Narkiewicz-Jodko A., Johnson B., Liebau J., Bhattacharyya S., Hati S. Role of oxidative stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) infection: a review. Protein J. 2020;39:644\u2013656. doi: 10.1007/s10930-020-09935-8.", "ArticleIdList": ["10.1007/s10930-020-09935-8", "PMC7587547", "33106987"]}, {"Citation": "Townsend B.E., Johnson R.W. Sulforaphane induces Nrf2 target genes and attenuates inflammatory gene expression in microglia from brain of young adult and aged mice. Exp. Gerontol. 2016;73:42\u201348. doi: 10.1016/j.exger.2015.11.004.", "ArticleIdList": ["10.1016/j.exger.2015.11.004", "PMC4713291", "26571201"]}, {"Citation": "Olagnier D., Lababidi R.R., Hadj S.B., Sze A., Liu Y., Naidu S.D., Ferrari M., Jiang Y., Chiang C., Beljanski V., Goulet M.L., Knatko E.V., Dinkova-Kostova A.T., Hiscott J., Lin R. Activation of Nrf2 signaling augments vesicular stomatitis virus oncolysis via autophagy-driven suppression of antiviral immunity. Mol. Ther. 2017;25:1900\u20131916. doi: 10.1016/j.ymthe.2017.04.022.", "ArticleIdList": ["10.1016/j.ymthe.2017.04.022", "PMC5542709", "28527723"]}, {"Citation": "Kobayashi E.H., Suzuki T., Funayama R., Nagashima T., Hayashi M., Sekine H., Tanaka N., Moriguchi T., Motohashi H., Nakayama K., Yamamoto M. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat. Commun. 2016;7:11624. doi: 10.1038/ncomms11624.", "ArticleIdList": ["10.1038/ncomms11624", "PMC4879264", "27211851"]}, {"Citation": "Jones S.A., Hunter C.A. Is IL-6 a key cytokine target for therapy in COVID-19? Nat. Rev. Immunol. 2021;21:337\u2013339. doi: 10.1038/s41577-021-00553-8.", "ArticleIdList": ["10.1038/s41577-021-00553-8", "PMC8043092", "33850327"]}, {"Citation": "Olagnier D., Farahani E., Thyrsted J., Blay-Cadanet J., Herengt A., Idorn M., Hait A., Hernaez B., Knudsen A., Iversen M.B., Schilling M., Jorgensen S.E., Thomsen M., Reinert L.S., Lappe M., Hoang H.D., Gilchrist V.H., Hansen A.L., Ottosen R., Nielsen C.G., Moller C., van der Horst D., Peri S., Balachandran S., Huang J., Jakobsen M., Svenningsen E.B., Poulsen T.B., Bartsch L., Thielke A.L., Luo Y., Alain T., Rehwinkel J., Alcami A., Hiscott J., Mogensen T.H., Paludan S.R., Holm C.K. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Nat. Commun. 2020;11:4938.", "ArticleIdList": ["PMC7532469", "33009401"]}, {"Citation": "Zhao S., Ghosh A., Lo C.S., Chenier I., Scholey J.W., Filep J.G., Ingelfinger J.R., Zhang S.L., Chan J.S.D. Nrf2 deficiency upregulates intrarenal angiotensin-converting Enzyme-2 and angiotensin 1\u20137 receptor expression and attenuates hypertension and nephropathy in diabetic mice. Endocrinology. 2018;159:836\u2013852. doi: 10.1210/en.2017-00752.", "ArticleIdList": ["10.1210/en.2017-00752", "PMC5774246", "29211853"]}, {"Citation": "Petry A., Weitnauer M., Gorlach A. Antioxid. RedoxSignal. 2010;13:467\u2013487. doi: 10.1089/ars.2009.3026.", "ArticleIdList": ["10.1089/ars.2009.3026", "20001746"]}, {"Citation": "Griendling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 1994;74:1141\u20131148. doi: 10.1161/01.res.74.6.1141.", "ArticleIdList": ["10.1161/01.res.74.6.1141", "8187280"]}, {"Citation": "Espinoza J.A., Gonzalez P.A., Kalergis A.M. Modulation of antiviral immunity by heme Oxygenase-1. Am. J. Pathol. 2017;187:487\u2013493. doi: 10.1016/j.ajpath.2016.11.011.", "ArticleIdList": ["10.1016/j.ajpath.2016.11.011", "28082120"]}, {"Citation": "Martinez-Sanchez G., Schwartz A., Donna V.D. Potential cytoprotective activity of ozone therapy in SARS-CoV-2/COVID-19. Antioxidants (Basel) 2020;9 doi: 10.3390/antiox9050389.", "ArticleIdList": ["10.3390/antiox9050389", "PMC7278582", "32384798"]}, {"Citation": "Sporn M.B., Liby K.T. NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer. 2012;12:564\u2013571. doi: 10.1038/nrc3278.", "ArticleIdList": ["10.1038/nrc3278", "PMC3836441", "22810811"]}, {"Citation": "Taguchi K., Yamamoto M. The KEAP1-NRF2 system in cancer. Front. Oncol. 2017;7:85. doi: 10.3389/fonc.2017.00085.", "ArticleIdList": ["10.3389/fonc.2017.00085", "PMC5415577", "28523248"]}, {"Citation": "Kensler T.W., Wakabayashi N. Nrf2: friend or foe for chemoprevention? Carcinogenesis. 2010;31:90\u201399. doi: 10.1093/carcin/bgp231.", "ArticleIdList": ["10.1093/carcin/bgp231", "PMC2802668", "19793802"]}, {"Citation": "Hayes J.D., McMahon M., Chowdhry S., Dinkova-Kostova A.T. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid. Redox.Signal. 2010;13:1713\u20131748. doi: 10.1089/ars.2010.3221.", "ArticleIdList": ["10.1089/ars.2010.3221", "20446772"]}, {"Citation": "Hu R., Saw C.L., Yu R., Kong A.N. Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: antioxidant coupled with antiinflammatory. Antioxid. Redox.Signal. 2010;13:1679\u20131698. doi: 10.1089/ars.2010.3276.", "ArticleIdList": ["10.1089/ars.2010.3276", "PMC2966483", "20486765"]}, {"Citation": "Wang L., Zhang C., Qin L., Xu J., Li X., Wang W., Kong L., Zhou T., Li X. The prognostic value of NRF2 in solid tumor patients: a meta-analysis. Oncotarget. 2018;9:1257\u20131265. doi: 10.18632/oncotarget.19838.", "ArticleIdList": ["10.18632/oncotarget.19838", "PMC5787436", "29416692"]}, {"Citation": "DeNicola G.M., Karreth F.A., Humpton T.J., Gopinathan A., Wei C., Frese K., Mangal D., Yu K.H., Yeo C.J., Calhoun E.S., Scrimieri F., Winter J.M., Hruban R.H., Iacobuzio-Donahue C., Kern S.E., Blair I.A., Tuveson D.A. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011;475:106\u2013109. doi: 10.1038/nature10189.", "ArticleIdList": ["10.1038/nature10189", "PMC3404470", "21734707"]}, {"Citation": "Kim Y.R., Oh J.E., Kim M.S., Kang M.R., Park S.W., Han J.Y., Eom H.S., Yoo N.J., Lee S.H. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J. Pathol. 2010;220:446\u2013451. doi: 10.1002/path.2653.", "ArticleIdList": ["10.1002/path.2653", "19967722"]}, {"Citation": "Padmanabhan B., Tong K.I., Ohta T., Nakamura Y., Scharlock M., Ohtsuji M., Kang M.I., Kobayashi A., Yokoyama S., Yamamoto M. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol. Cell. 2006;21:689\u2013700. doi: 10.1016/j.molcel.2006.01.013.", "ArticleIdList": ["10.1016/j.molcel.2006.01.013", "16507366"]}, {"Citation": "Singh A., Misra V., Thimmulappa R.K., Lee H., Ames S., Hoque M.O., Herman J.G., Baylin S.B., Sidransky D., Gabrielson E., Brock M.V., Biswal S. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 2006;3 doi: 10.1371/journal.pmed.0030420.", "ArticleIdList": ["10.1371/journal.pmed.0030420", "PMC1584412", "17020408"]}, {"Citation": "Wang R., An J., Ji F., Jiao H., Sun H., Zhou D. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem. Biophys. Res. Commun. 2008;373:151\u2013154. doi: 10.1016/j.bbrc.2008.06.004.", "ArticleIdList": ["10.1016/j.bbrc.2008.06.004", "18555005"]}, {"Citation": "Adam J., Hatipoglu E., O'Flaherty L., Ternette N., Sahgal N., Lockstone H., Baban D., Nye E., Stamp G.W., Wolhuter K., Stevens M., Fischer R., Carmeliet P., Maxwell P.H., Pugh C.W., Frizzell N., Soga T., Kessler B.M., El-Bahrawy M., Ratcliffe P.J., Pollard P.J. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell. 2011;20:524\u2013537. doi: 10.1016/j.ccr.2011.09.006.", "ArticleIdList": ["10.1016/j.ccr.2011.09.006", "PMC3202623", "22014577"]}, {"Citation": "Sheridan C. Second oral MS drug wins FDA nod. Nat. Biotechnol. 2013;31:373. doi: 10.1038/nbt0513-373a.", "ArticleIdList": ["10.1038/nbt0513-373a", "23657376"]}, {"Citation": "Hur W., Gray N.S. Small molecule modulators of antioxidant response pathway. Curr. Opin. Chem. Biol. 2011;15:162\u2013173. doi: 10.1016/j.cbpa.2010.12.009.", "ArticleIdList": ["10.1016/j.cbpa.2010.12.009", "21195017"]}, {"Citation": "Magesh S., Chen Y., Hu L. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med. Res. Rev. 2012;32:687\u2013726. doi: 10.1002/med.21257.", "ArticleIdList": ["10.1002/med.21257", "PMC3393814", "22549716"]}, {"Citation": "McMahon M., Lamont D.J., Beattie K.A., Hayes J.D. Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc. Natl. Acad. Sci. U. S. A. 2010;107:18838\u201318843. doi: 10.1073/pnas.1007387107.", "ArticleIdList": ["10.1073/pnas.1007387107", "PMC2973898", "20956331"]}, {"Citation": "Wilson A.J., Kerns J.K., Callahan J.F., Moody C.J. Keap calm, and carry on covalently. J. Med. Chem. 2013;56:7463\u20137476. doi: 10.1021/jm400224q.", "ArticleIdList": ["10.1021/jm400224q", "23837912"]}, {"Citation": "Albrecht P., Bouchachia I., Goebels N., Henke N., Hofstetter H.H., Issberner A., Kovacs Z., Lewerenz J., Lisak D., Maher P., Mausberg A.K., Quasthoff K., Zimmermann C., Hartung H.P., Methner A. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J. Neuroinflammation. 2012;9:163. doi: 10.1186/1742-2094-9-163.", "ArticleIdList": ["10.1186/1742-2094-9-163", "PMC3419128", "22769044"]}, {"Citation": "Venci J.V., Gandhi M.A. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis. Ann. Pharmacother. 2013;47:1697\u20131702. doi: 10.1177/1060028013509232.", "ArticleIdList": ["10.1177/1060028013509232", "24259625"]}, {"Citation": "Cross S.A., Cook D.R., Chi A.W., Vance P.J., Kolson L.L., Wong B.J., Jordan-Sciutto K.L., Kolson D.L. Dimethyl fumarate, an immune modulator and inducer of the antioxidant response, suppresses HIV replication and macrophage-mediated neurotoxicity: a novel candidate for HIV neuroprotection. J. Immunol. 2011;187:5015\u20135025. doi: 10.4049/jimmunol.1101868.", "ArticleIdList": ["10.4049/jimmunol.1101868", "PMC3208057", "21976775"]}, {"Citation": "Furuya A.K., Sharifi H.J., Jellinger R.M., Cristofano P., Shi B., Noronha C.M. Sulforaphane inhibits HIV infection of macrophages through Nrf2. PLoS Pathog. 2016;12 doi: 10.1371/journal.ppat.1005581.", "ArticleIdList": ["10.1371/journal.ppat.1005581", "PMC4836681", "27093399"]}, {"Citation": "Kesic M.J., Simmons S.O., Bauer R., Jaspers I. Nrf2 expression modifies influenza a entry and replication in nasal epithelial cells. Free Radic. Biol. Med. 2011;51:444\u2013453. doi: 10.1016/j.freeradbiomed.2011.04.027.", "ArticleIdList": ["10.1016/j.freeradbiomed.2011.04.027", "PMC3135631", "21549835"]}, {"Citation": "Yu J.S., Chen W.C., Tseng C.K., Lin C.K., Hsu Y.C., Chen Y.H., Lee J.C. Sulforaphane suppresses hepatitis C virus replication by up-regulating heme Oxygenase-1 expression through PI3K/Nrf2 pathway. PLoS One. 2016;11 doi: 10.1371/journal.pone.0152236.", "ArticleIdList": ["10.1371/journal.pone.0152236", "PMC4811417", "27023634"]}, {"Citation": "Schachtele S.J., Hu S., Lokensgard J.R. Modulation of experimental herpes encephalitis-associated neurotoxicity through sulforaphane treatment. PLoS One. 2012;7 doi: 10.1371/journal.pone.0036216.", "ArticleIdList": ["10.1371/journal.pone.0036216", "PMC3338688", "22558388"]}, {"Citation": "Yore M.M., Kettenbach A.N., Sporn M.B., Gerber S.A., Liby K.T. Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR. PLoS One. 2011;6 doi: 10.1371/journal.pone.0022862.", "ArticleIdList": ["10.1371/journal.pone.0022862", "PMC3144948", "21818401"]}, {"Citation": "Blewett M.M., Xie J., Zaro B.W., Backus K.M., Altman A., Teijaro J.R., Cravatt B.F. Chemical proteomic map of dimethyl fumarate-sensitive cysteines in primary human T cells. Sci. Signal. 2016;9:rs10. doi: 10.1126/scisignal.aaf7694.", "ArticleIdList": ["10.1126/scisignal.aaf7694", "PMC5068918", "27625306"]}, {"Citation": "Hosseini A., Masjedi A., Baradaran B., Hojjat-Farsangi M., Ghalamfarsa G., Anvari E., Jadidi-Niaragh F. Dimethyl fumarate: regulatory effects on the immune system in the treatment of multiple sclerosis. J. Cell. Physiol. 2019;234:9943\u20139955. doi: 10.1002/jcp.27930.", "ArticleIdList": ["10.1002/jcp.27930", "30536402"]}, {"Citation": "Schulze-Topphoff U., Varrin-Doyer M., Pekarek K., Spencer C.M., Shetty A., Sagan S.A., Cree B.A., Sobel R.A., Wipke B.T., Steinman L., Scannevin R.H., Zamvil S.S. Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc. Natl. Acad. Sci. U. S. A. 2016;113:4777\u20134782. doi: 10.1073/pnas.1603907113.", "ArticleIdList": ["10.1073/pnas.1603907113", "PMC4855599", "27078105"]}, {"Citation": "Hahm E.R., Singh S.V. Sulforaphane inhibits constitutive and interleukin-6-induced activation of signal transducer and activator of transcription 3 in prostate cancer cells. Cancer Prev. Res. (Phila.) 2010;3:484\u2013494. doi: 10.1158/1940-6207.CAPR-09-0250.", "ArticleIdList": ["10.1158/1940-6207.CAPR-09-0250", "PMC2853726", "20233902"]}, {"Citation": "Heiss E., Herhaus C., Klimo K., Bartsch H., Gerhauser C. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J. Biol. Chem. 2001;276:32008\u201332015. doi: 10.1074/jbc.M104794200.", "ArticleIdList": ["10.1074/jbc.M104794200", "11410599"]}, {"Citation": "Baell J., Walters M.A. Chemistry: chemical con artists foil drug discovery. Nature. 2014;513:481\u2013483. doi: 10.1038/513481a.", "ArticleIdList": ["10.1038/513481a", "25254460"]}, {"Citation": "Richardson B.G., Jain A.D., Speltz T.E., Moore T.W. Non-electrophilic modulators of the canonical Keap1/Nrf2 pathway. Bioorg. Med. Chem. Lett. 2015;25:2261\u20132268. doi: 10.1016/j.bmcl.2015.04.019.", "ArticleIdList": ["10.1016/j.bmcl.2015.04.019", "PMC4643947", "25937010"]}, {"Citation": "Dahlin J.L., Walters M.A. The essential roles of chemistry in high-throughput screening triage. FutureMed. Chem. 2014;6:1265\u20131290. doi: 10.4155/fmc.14.60.", "ArticleIdList": ["10.4155/fmc.14.60", "PMC4465542", "25163000"]}, {"Citation": "Zhuang C., Wu Z., Xing C., Miao Z. Small molecules inhibiting Keap1-Nrf2 protein-protein interactions: a novel approach to activate Nrf2 function. Med. Chem. Comm. 2017;8:286\u2013294. doi: 10.1039/c6md00500d.", "ArticleIdList": ["10.1039/c6md00500d", "PMC6072482", "30108745"]}, {"Citation": "Balogun E., Hoque M., Gong P., Killeen E., Green C.J., Foresti R., Alam J., Motterlini R. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem. J. 2003;371:887\u2013895. doi: 10.1042/BJ20021619.", "ArticleIdList": ["10.1042/BJ20021619", "PMC1223348", "12570874"]}, {"Citation": "Soetikno V., Sari F.R., Lakshmanan A.P., Arumugam S., Harima M., Suzuki K., Kawachi H., Watanabe K. Curcumin alleviates oxidative stress, inflammation, and renal fibrosis in remnant kidney through the Nrf2-keap1 pathway. Mol. Nutr. Food Res. 2013;57:1649\u20131659. doi: 10.1002/mnfr.201200540.", "ArticleIdList": ["10.1002/mnfr.201200540", "23174956"]}, {"Citation": "Coles B.F., Kadlubar F.F. Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs? Biofactors. 2003;17:115\u2013130. doi: 10.1002/biof.5520170112.", "ArticleIdList": ["10.1002/biof.5520170112", "12897434"]}, {"Citation": "Pompella A., Visvikis A., Paolicchi A., De T., Casini V.A.F. The changing faces of glutathione, a cellular protagonist. Biochem. Pharmacol. 2003;66:1499\u20131503. doi: 10.1016/s0006-2952(03)00504-5.", "ArticleIdList": ["10.1016/s0006-2952(03)00504-5", "14555227"]}, {"Citation": "Kosower N.S., Kosower E.M. The glutathione status of cells. Int. Rev. Cytol. 1978;54:109\u2013160. doi: 10.1016/s0074-7696(08)60166-7.", "ArticleIdList": ["10.1016/s0074-7696(08)60166-7", "42630"]}, {"Citation": "Satoh T., McKercher S.R., Lipton S.A. Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs. Free Radic. Biol. Med. 2013;65:645\u2013657. doi: 10.1016/j.freeradbiomed.2013.07.022.", "ArticleIdList": ["10.1016/j.freeradbiomed.2013.07.022", "PMC3859717", "23892355"]}, {"Citation": "Copple I.M., Shelton L.M., Walsh J., Kratschmar D.V., Lister A., Odermatt A., Goldring C.E., Dinkova-Kostova A.T., Honda T., Park B.K. Chemical tuning enhances both potency toward nrf2 and in vitro therapeutic index of triterpenoids. Toxicol. Sci. 2014;140:462\u2013469. doi: 10.1093/toxsci/kfu080.", "ArticleIdList": ["10.1093/toxsci/kfu080", "PMC4120102", "24798383"]}, {"Citation": "Jo J., Ibrahim L., Iaconelli J., Kwak J., Kumar M., Jung Y., Lairson L.L., Chatterjee A.K., Schultz P.G., Bollong M.J., Yun H. Discovery and SAR studies of 3-amino-4-(phenylsulfonyl)tetrahydrothiophene 1,1-dioxides as non-electrophilic antioxidant response element (ARE) activators. Bioorg. Chem. 2021;108:104614.", "ArticleIdList": ["33508678"]}, {"Citation": "Lipton S.A., Rezaie T., Nutter A., Lopez K.M., Parker J., Kosaka K., Satoh T., McKercher S.R., Masliah E., Nakanishi N. Therapeutic advantage of pro-electrophilic drugs to activate the Nrf2/ARE pathway in Alzheimer's disease models. Cell Death Dis. 2016;7 (e2499-doi:10.1038/cddis.2016.389)", "ArticleIdList": ["PMC5261011", "27906174"]}, {"Citation": "Satoh T., Lipton S. Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate. F1000Res. 2017;6:2138. doi: 10.12688/f1000research.12111.1.", "ArticleIdList": ["10.12688/f1000research.12111.1", "PMC5730864", "29263788"]}, {"Citation": "Bains J.S., Shaw C.A. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain. Res. BrainRes. Rev. 1997;25:335\u2013358. doi: 10.1016/s0165-0173(97)00045-3.", "ArticleIdList": ["10.1016/s0165-0173(97)00045-3", "9495562"]}, {"Citation": "Tong K.I., Katoh Y., Kusunoki H., Itoh K., Tanaka T., Yamamoto M. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol. Cell. Biol. 2006;26:2887\u20132900. doi: 10.1128/MCB.26.8.2887-2900.2006.", "ArticleIdList": ["10.1128/MCB.26.8.2887-2900.2006", "PMC1446969", "16581765"]}, {"Citation": "Beamer L.J., Li X., Bottoms C.A., Hannink M. Conserved solvent and side-chain interactions in the 1.35 angstrom structure of the kelch domain of Keap1. Acta Crystallogr.D Biol. Crystallogr. 2005;61:1335\u20131342. doi: 10.1107/S0907444905022626.", "ArticleIdList": ["10.1107/S0907444905022626", "16204884"]}, {"Citation": "Tong K.I., Padmanabhan B., Kobayashi A., Shang C., Hirotsu Y., Yokoyama S., Yamamoto M. Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. Mol. Cell. Biol. 2007;27:7511\u20137521. doi: 10.1128/MCB.00753-07.", "ArticleIdList": ["10.1128/MCB.00753-07", "PMC2169061", "17785452"]}, {"Citation": "Jiang Z.Y., Lu M.C., You Q.D. Discovery and development of kelch-like ECH-associated protein 1. Nuclear factor erythroid 2-related factor 2 (KEAP1:NRF2) protein-protein interaction inhibitors: achievements, challenges, and future directions. J. Med. Chem. 2016;59:10837\u201310858. doi: 10.1021/acs.jmedchem.6b00586.", "ArticleIdList": ["10.1021/acs.jmedchem.6b00586", "27690435"]}, {"Citation": "Chen Y., Inoyama D., Kong A.N., Beamer L.J., Hu L. Kinetic analyses of Keap1-Nrf2 interaction and determination of the minimal Nrf2 peptide sequence required for Keap1 binding using surface plasmon resonance. Chem. Biol. Drug Des. 2011;78:1014\u20131021. doi: 10.1111/j.1747-0285.2011.01240.x.", "ArticleIdList": ["10.1111/j.1747-0285.2011.01240.x", "PMC3218206", "21920027"]}, {"Citation": "Inoyama D., Chen Y., Huang X., Beamer L.J., Kong A.N., Hu L. Optimization of fluorescently labeled Nrf2 peptide probes and the development of a fluorescence polarization assay for the discovery of inhibitors of Keap1-Nrf2 interaction. J. Biomol. Screen. 2012;17:435\u2013447. doi: 10.1177/1087057111430124.", "ArticleIdList": ["10.1177/1087057111430124", "PMC3309107", "22156223"]}, {"Citation": "Hancock R., Bertrand H.C., Tsujita T., Naz S., El-Bakry A., Laoruchupong J., Hayes J.D., Wells G. Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction. Free Radic. Biol. Med. 2012;52:444\u2013451. doi: 10.1016/j.freeradbiomed.2011.10.486.", "ArticleIdList": ["10.1016/j.freeradbiomed.2011.10.486", "22107959"]}, {"Citation": "Hancock R., Schaap M., Pfister H., Wells G. Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction with improved binding and cellular activity. Org. Biomol. Chem. 2013;11:3553\u20133557.", "ArticleIdList": ["23615671"]}, {"Citation": "Lu M.C., Chen Z.Y., Wang Y.L., Jiang Y.L., Yuan Z.W., You Q.D., Jiang Z.Y. Binding thermodynamics and kinetics guided optimization of potent Keap1-Nrf2 peptide inhibitors. RSC Adv. 2015;5:85983\u201385987. doi: 10.1039/c5ra16262a.", "ArticleIdList": ["10.1039/c5ra16262a"]}, {"Citation": "Lu M., Liu T., Jiao Q., Ji J., Tao M., Liu Y., You Q., Jiang Z. Discovery of a Keap1-dependent peptide PROTAC to knockdown tau by ubiquitination-proteasome degradation pathway. Eur. J. Med. Chem. 2018;146:251\u2013259. doi: 10.1016/j.ejmech.2018.01.063.", "ArticleIdList": ["10.1016/j.ejmech.2018.01.063", "29407955"]}, {"Citation": "Guntas G., Lewis S.M., Mulvaney K.M., Cloer E.W., Tripathy A., Lane T.R., Major M.B., Kuhlman B. Engineering a genetically encoded competitive inhibitor of the KEAP1-NRF2 interaction via structure-based design and phage display. Protein Eng. Des. Sel. 2016;29:1\u20139. doi: 10.1093/protein/gzv055.", "ArticleIdList": ["10.1093/protein/gzv055", "PMC4678006", "26489878"]}, {"Citation": "Lu M.C., Jiao Q., Liu T., Tan S.J., Zhou H.S., You Q.D., Jiang Z.Y. Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency. Eur. J. Med. Chem. 2018;143:1578\u20131589. doi: 10.1016/j.ejmech.2017.10.052.", "ArticleIdList": ["10.1016/j.ejmech.2017.10.052", "29117896"]}, {"Citation": "Colarusso S., De S.D., Frattarelli T., Andreini M., Cerretani M., Missineo A., Moretti D., Tambone S., Kempf G., Augustin M., Steinbacher S., Munoz-Sanjuan I., Park L., Summa V., Tomei L., Bresciani A., Dominguez C., Toledo-Sherman L., Bianchi E. Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interaction. Bioorg. Med. Chem. 2020;28:115738. doi: 10.1016/j.bmc.2020.115738.", "ArticleIdList": ["10.1016/j.bmc.2020.115738", "33065433"]}, {"Citation": "Mou Y., Wen S., Li Y.X., Gao X.X., Zhang X., Jiang Z.Y. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors. Eur. J. Med. Chem. 2020;202 doi: 10.1016/j.ejmech.2020.112532.", "ArticleIdList": ["10.1016/j.ejmech.2020.112532", "32668381"]}, {"Citation": "Slastnikova T.A., Ulasov A.V., Rosenkranz A.A., Sobolev A.S. Targeted intracellular delivery of antibodies: the state of the art. Front. Pharmacol. 2018;9 (1208-doi:10.3389/fphar.2018.01208)", "ArticleIdList": ["PMC6207587", "30405420"]}, {"Citation": "Koide A., Koide S. Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol. Biol. 2007;352:95\u2013109. doi: 10.1385/1-59745-187-8:95.", "ArticleIdList": ["10.1385/1-59745-187-8:95", "17041261"]}, {"Citation": "Koide A., Wojcik J., Gilbreth R.N., Hoey R.J., Koide S. Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold. J. Mol. Biol. 2012;415:393\u2013405. doi: 10.1016/j.jmb.2011.12.019.", "ArticleIdList": ["10.1016/j.jmb.2011.12.019", "PMC3260337", "22198408"]}, {"Citation": "Gilbreth R.N., Koide S. Structural insights for engineering binding proteins based on non-antibody scaffolds. Curr. Opin. Struct. Biol. 2012;22:413\u2013420. doi: 10.1016/j.sbi.2012.06.001.", "ArticleIdList": ["10.1016/j.sbi.2012.06.001", "PMC3423532", "22749196"]}, {"Citation": "Lindgren M., Hallbrink M., Prochiantz A., Langel U. Cell-penetrating peptides. Trends Pharmacol. Sci. 2000;21:99\u2013103. doi: 10.1016/s0165-6147(00)01447-4.", "ArticleIdList": ["10.1016/s0165-6147(00)01447-4", "10689363"]}, {"Citation": "Heitz F., Morris M.C., Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol. 2009;157:195\u2013206. doi: 10.1111/j.1476-5381.2009.00057.x.", "ArticleIdList": ["10.1111/j.1476-5381.2009.00057.x", "PMC2697800", "19309362"]}, {"Citation": "Steel R., Cowan J., Payerne E., O'Connell M.A., Searcey M. Anti-inflammatory effect of a cell-penetrating peptide targeting the Nrf2/Keap1 interaction. ACS Med. Chem. Lett. 2012;3:407\u2013410. doi: 10.1021/ml300041g.", "ArticleIdList": ["10.1021/ml300041g", "PMC3350226", "22582137"]}, {"Citation": "Zhao J., Redell J.B., Moore A.N., Dash P.K. A novel strategy to activate cytoprotective genes in the injured brain. Biochem. Biophys. Res. Commun. 2011;407:501\u2013506. doi: 10.1016/j.bbrc.2011.03.046.", "ArticleIdList": ["10.1016/j.bbrc.2011.03.046", "PMC4264351", "21414291"]}, {"Citation": "Tu J., Zhang X., Zhu Y., Dai Y., Li N., Yang F., Zhang Q., Brann D.W., Wang R. Cell-permeable peptide targeting the Nrf2-Keap1 interaction: a potential novel therapy for global cerebral ischemia. J. Neurosci. 2015;35:14727\u201314739. doi: 10.1523/JNEUROSCI.1304-15.2015.", "ArticleIdList": ["10.1523/JNEUROSCI.1304-15.2015", "PMC4635127", "26538645"]}, {"Citation": "Pallesen J.S., Tran K.T., Bach A. Non-covalent small-molecule kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 (Keap1-Nrf2) inhibitors and their potential for targeting central nervous system diseases. J. Med. Chem. 2018 doi: 10.1021/acs.jmedchem.8b00358.", "ArticleIdList": ["10.1021/acs.jmedchem.8b00358", "29750408"]}, {"Citation": "Schmoll D., Engel C.K., Glombik H. The Keap1-Nrf2 protein-protein interaction: a suitable target for small molecules. Drug Discov. Today Technol. 2017;24:11\u201317. doi: 10.1016/j.ddtec.2017.10.001.", "ArticleIdList": ["10.1016/j.ddtec.2017.10.001", "29233294"]}, {"Citation": "Jiang Z.Y., Lu M.C., Xu L.L., Yang T.T., Xi M.Y., Xu X.L., Guo X.K., Zhang X.J., You Q.D., Sun H.P. Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis. J. Med. Chem. 2014;57:2736\u20132745. doi: 10.1021/jm5000529.", "ArticleIdList": ["10.1021/jm5000529", "24512214"]}, {"Citation": "Jiang Z.Y., Xu L.L., Lu M.C., Chen Z.Y., Yuan Z.W., Xu X.L., Guo X.K., Zhang X.J., Sun H.P., You Q.D. Structure-activity and structure-property relationship and exploratory in vivo evaluation of the nanomolar Keap1-Nrf2 protein-protein interaction inhibitor. J. Med. Chem. 2015;58:6410\u20136421. doi: 10.1021/acs.jmedchem.5b00185.", "ArticleIdList": ["10.1021/acs.jmedchem.5b00185", "26258437"]}, {"Citation": "Davies T.G., Wixted W.E., Coyle J.E., Griffiths-Jones C., Hearn K., McMenamin R., Norton D., Rich S.J., Richardson C., Saxty G., Willems H.M., Woolford A.J., Cottom J.E., Kou J.P., Yonchuk J.G., Feldser H.G., Sanchez Y., Foley J.P., Bolognese B.J., Logan G., Podolin P.L., Yan H., Callahan J.F., Heightman T.D., Kerns J.K. Monoacidic inhibitors of the kelch-like ECH-associated protein 1: nuclear factor erythroid 2-related factor 2 (KEAP1:NRF2) protein-protein interaction with high cell potency identified by fragment-based discovery. J. Med. Chem. 2016;59:3991\u20134006. doi: 10.1021/acs.jmedchem.6b00228.", "ArticleIdList": ["10.1021/acs.jmedchem.6b00228", "27031670"]}, {"Citation": "Matsson P., Doak B.C., Over B., Kihlberg J. Cell permeability beyond the rule of 5. Adv. Drug Deliv. Rev. 2016;101:42\u201361. doi: 10.1016/j.addr.2016.03.013.", "ArticleIdList": ["10.1016/j.addr.2016.03.013", "27067608"]}, {"Citation": "Liu H., Zeng F., Zhang M., Huang F., Wang J., Guo J., Liu C., Wang H. Emerging landscape of cell penetrating peptide in reprogramming and gene editing. J. Control. Release. 2016;226:124\u2013137. doi: 10.1016/j.jconrel.2016.02.002.", "ArticleIdList": ["10.1016/j.jconrel.2016.02.002", "26849918"]}, {"Citation": "Koren E., Torchilin V.P. Cell-penetrating peptides: breaking through to the other side. Trends Mol. Med. 2012;18:385\u2013393. doi: 10.1016/j.molmed.2012.04.012.", "ArticleIdList": ["10.1016/j.molmed.2012.04.012", "22682515"]}, {"Citation": "Bechara C., Sagan S. Cell-penetrating peptides: 20 years later, where do we stand? FEBS Lett. 2013;587:1693\u20131702. doi: 10.1016/j.febslet.2013.04.031.", "ArticleIdList": ["10.1016/j.febslet.2013.04.031", "23669356"]}, {"Citation": "Copolovici D.M., Langel K., Eriste E., Langel U. Cell-penetrating peptides: design, synthesis, and applications. ACS Nano. 2014;8:1972\u20131994. doi: 10.1021/nn4057269.", "ArticleIdList": ["10.1021/nn4057269", "24559246"]}, {"Citation": "Richard J.P., Melikov K., Vives E., Ramos C., Verbeure B., Gait M.J., Chernomordik L.V., Lebleu B. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 2003;278:585\u2013590. doi: 10.1074/jbc.M209548200.", "ArticleIdList": ["10.1074/jbc.M209548200", "12411431"]}, {"Citation": "Takenobu T., Tomizawa K., Matsushita M., Li S.T., Moriwaki A., Lu Y.F., Matsui H. Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol. Cancer Ther. 2002;1:1043\u20131049.", "ArticleIdList": ["12481427"]}, {"Citation": "Ulasov A.V., Rosenkranz A.A., Sobolev A.S. Transcription factors: time to deliver. J. Control. Release. 2018;269:24\u201335. doi: 10.1016/j.jconrel.2017.11.004.", "ArticleIdList": ["10.1016/j.jconrel.2017.11.004", "29113792"]}, {"Citation": "Zinovkin R.A., Grebenchikov O.A. Transcription factor Nrf2 as a potential therapeutic target for prevention of cytokine storm in COVID-19 patients. Biochemistry (Mosc) 2020:833\u2013837. doi: 10.1134/S0006297920070111.", "ArticleIdList": ["10.1134/S0006297920070111", "PMC7356136", "33040727"]}, {"Citation": "Cuadrado A., Pajares M., Benito C., Jimenez-Villegas J., Escoll M., Fernandez-Gines R., Garcia Yague A.J., Lastra D., Manda G., Rojo A.I., Dinkova-Kostova A.T. Can activation of NRF2 be a strategy against COVID-19? Trends Pharmacol. Sci. 2020;41:598\u2013610. doi: 10.1016/j.tips.2020.07.003.", "ArticleIdList": ["10.1016/j.tips.2020.07.003", "PMC7359808", "32711925"]}, {"Citation": "Gebauer M., Skerra A. Engineered protein scaffolds as next-generation therapeutics. Annu. Rev. Pharmacol. Toxicol. 2020;60:391\u2013415. doi: 10.1146/annurev-pharmtox-010818-021118.", "ArticleIdList": ["10.1146/annurev-pharmtox-010818-021118", "31914898"]}, {"Citation": "Wu T., Yoon H., Xiong Y., Dixon-Clarke S.E., Nowak R.P., Fischer E.S. Targeted protein degradation as a powerful research tool in basic biology and drug target discovery. Nat. Struct. Mol. Biol. 2020;27:605\u2013614. doi: 10.1038/s41594-020-0438-0.", "ArticleIdList": ["10.1038/s41594-020-0438-0", "PMC7923177", "32541897"]}, {"Citation": "Daniels D.L., Riching K.M., Urh M. Monitoring and deciphering protein degradation pathways inside cells. Drug Discov. Today Technol. 2019;31:61\u201368. doi: 10.1016/j.ddtec.2018.12.001.", "ArticleIdList": ["10.1016/j.ddtec.2018.12.001", "31200861"]}, {"Citation": "Bondeson D.P., Mares A., Smith I.E., Ko E., Campos S., Miah A.H., Mulholland K.E., Routly N., Buckley D.L., Gustafson J.L., Zinn N., Grandi P., Shimamura S., Bergamini G., Faelth-Savitski M., Bantscheff M., Cox C., Gordon D.A., Willard R.R., Flanagan J.J., Casillas L.N., Votta B.J., Besten W., Famm K., Kruidenier L., Carter P.S., Harling J.D., Churcher I., Crews C.M. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 2015;11:611\u2013617. doi: 10.1038/nchembio.1858.", "ArticleIdList": ["10.1038/nchembio.1858", "PMC4629852", "26075522"]}, {"Citation": "Slastnikova T.A., Rosenkranz A.A., Gulak P.V., Schiffelers R.M., Lupanova T.N., Khramtsov Y.V., Zalutsky M.R., Sobolev A.S. Modular nanotransporters: a multipurpose in vivo working platform for targeted drug delivery. Int. J. Nanomedicine. 2012;7:467\u2013482. doi: 10.2147/IJN.S28249.", "ArticleIdList": ["10.2147/IJN.S28249", "PMC3277434", "22346349"]}, {"Citation": "Torchilin V.P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat. Rev. Drug Discov. 2014;13:813\u2013827. doi: 10.1038/nrd4333.", "ArticleIdList": ["10.1038/nrd4333", "PMC4489143", "25287120"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "8", "Day": "23"}, {"Year": "2021", "Month": "10", "Day": "22"}, {"Year": "2021", "Month": "10", "Day": "27"}, {"Year": "2021", "Month": "11", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "1", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "11", "Day": "4", "Hour": "5", "Minute": "35"}, {"Year": "2021", "Month": "10", "Day": "31"}], "PublicationStatus": "ppublish", "ArticleIdList": ["34732330", "PMC8557391", "10.1016/j.lfs.2021.120111", "S0024-3205(21)01098-5"]}}], "PubmedBookArticle": []}